Daclatasvir Dihydrochloride Intermediate CAS 1007882-23-6 Purity >98.0% (HPLC)

Short Description:

Daclatasvir Dihydrochloride Intermediate Ⅱ 

Synonyms: Daclatasvir T-Butyl Ester 

CAS: 1007882-23-6

Purity: >98.0% (HPLC)

Appearance: Light Yellow to Yellow Powder 

Intermediate of Daclatasvir Dihydrochloride CAS 1009119-65-6

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of Daclatasvir Dihydrochloride Intermediate (CAS: 1007882-23-6) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, small and bulk quantities available. Purchase Daclatasvir Dihydrochloride Intermediates, Please contact: alvin@ruifuchem.com

Chemical Properties:

Chemical Name Di-tert-Butyl (2S,2'S)-2,2'-(4,4'-Biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-Pyrrolidinecarboxylate) 
Synonyms Daclatasvir Intermediate Ⅱ; Dacaltasvir Intermediate 02; Daclatasvir T-Butyl Ester; Bis(2-Methyl-2-Propanyl) (2S,2'S)-2,2'-[4,4'-Biphenyldiylbis(1H-Imidazole-4,2-diyl)]di(1-Pyrrolidinecarboxylate); Di-tert-butyl 2,2′-([1,1′-Biphenyl]-4,4′-diylbis(1H-Imidazole-5,2-diyl))(2S,2’S)-bis(Pyridineidine-1-Carboxylate); (2S,2’S)-2,2’-([1,1’-Biphenyl]-4,4’-diyldi-1H-Imidazole-5,2-diyl)bis-1-Pyrrolidinecarboxylic Acid 1,1’-Bis(1,1-Dimethylethyl) Ester; Daclatasvir Impurity 4
Stock Status In Stock, Commercial Production  
CAS Number 1007882-23-6
Molecular Formula C40H51ClN8O6
Molecular Weight 775.35 g/mol
Boiling Point 890.2±65.0℃ at 760 mmHg 
Density 1.220±0.06 g/cm3 
COA & MSDS Available
Origin Shanghai, China
Category   Intermediate of Daclatasvir Dihydrochloride (CAS: 1009119-65-6)  
Brand Ruifu Chemical

Specifications:

Items Specifications  Results
Appearance Light Yellow to Yellow Powder
Light Yellow Powder     
Loss on Drying <1.00% 0.65% 
Maximum Single Impurity <1.00% 0.45%
Total Impurities <2.00% 1.24%
Purity / Analysis Method >98.0% (HPLC)  98.76% 
Infrared Spectrum Consistent with Structure Complies 
1H NMR Spectrum Consistent with Structure Complies
Conclusion The product has been tested and complies with the given specifications
Application Intermediate of Daclatasvir Dihydrochloride (CAS: 1009119-65-6)

Package/Storage/Shipping:

Package: Fluorinated Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery. 

Advantages:

Sufficient Capacity: Sufficient facilities and technicians

Professional Service: One stop purchasing service

OEM Package: Custom package and label available

Fast Delivery: If within stock, three days delivery guaranteed

Stable Supply: Maintain reasonable stock    

Technical Support: Technology solution available

Custom Synthesis Service: Ranged from grams to kilos

High Quality: Established a complete quality assurance system

FAQ:

How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com 

15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.

Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.

Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.

Quality AssuranceStrict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.

SamplesMost products provide free samples for quality evaluation, shipping cost should be paid by customers.

Factory AuditFactory audit welcome. Please make an appointment in advance.

MOQ? No MOQ. Small order is acceptable.

Delivery Time? If within stock, three days delivery guaranteed.

TransportationBy Express (FedEx, DHL), by Air, by Sea.

Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.

Custom SynthesisCan provide custom synthesis services to best fit your research needs.

Payment TermsProforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc. 

Application:

Di-tert-Butyl (2S,2'S)-2,2'-(4,4'-Biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-Pyrrolidinecarboxylate) (CAS: 1007882-23-6) is an intermediate of Daclatasvir Dihydrochloride (CAS: 1009119-65-6).
Daclatasvir (Daklinza) has obtained "priority review" status, combined with Sorafenib for the treatment of genotype III adult patients with chronic hepatitis C. Daklinza has been the first drug that has been proved of being effective in the treatment of genotype III hepatitis C virus infection without the co-administration with interferon or ribavirin. Interferon and Ribavirin are two drugs approved by FDA for the treatment of hepatitis C virus infection. Hepatitis C is a viral disease that can cause inflammation of the liver, resulting in decreased liver function or liver failure. Most patients infected with hepatitis C have no symptoms until liver damage becomes apparent, which may take several years. Globally, genotype III hepatitis C is the second most common genotype of hepatitis C after genotype 1 hepatitis C and is considered to be one of the most refractory genotype diseases. Daklinza is a pan-genotype NS5A replication complex inhibitor, with efficacy of inhibition of RNA replication and viral assembly, dual antiviral effect. For in vitro studies, Daklinza has been demonstrated to have anti-viral effect against genotype 1~6 hepatitis C virus. Daklinza is accompanied by a warning that the combination of amiodarone, Daklinza and Sofosbuvir may cause severe reduced heart rate. Daklinza is an oral tablet with the recommended dose of 60 mg for 1 times/d, in conjunction with Sofosbuvir for a total of 12 weeks.
Research and development company: Bristol-Myers Squibb.
Patent Literature: WO 2008021927A2 (August 9, 2007).
Time of marketing: July 24, 2015 listed in the United States, trade name Daklinza.
Indications: Used in combination with Sofosbuvir for the treatment of genotype 3 chronic hepatitis C (HCV) infection.
Mechanism of action: HCV nonstructural protein 5A (NS5A) inhibitors. Adverse reactions: headaches and fatigue.
Formulation and specifications: Tablets, 30 and 60mg. 

  • Write your message here and send it to us